Measurement of CSF a-synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer's disease.

Previous studies have indicated the potential of cerebrospinal fluid (CSF) a-synuclein (a-syn) to be an additional biomarker for improving differential diagnosis of Alzheimer's disease (AD). We evaluated a-syn diagnostic performance across a well-characterized patient cohort with long-term foll...

Full description

Bibliographic Details
Authors: Garcia-Ayllon, Maria-Salud, Monge-Argiles, Jose-Antonio, Monge-Garcia, Victoria, Navarrete, Francisco, Cortes-Gomez, Maria-Angeles, Sanchez-Paya, Jose, Manzanares, Jorge, Gasparini-Berenguer, Ruth, Leiva-Santana, Carlos, Saez-Valero, Javier
Format: article
Status:Published version
Publication Date:2019
Country:España
Institution:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
Repository:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
OAI Identifier:oai:isabial.fundanetsuite.com:p3536
Online Access:https://isabial.portalinvestigacion.com/publicaciones3536
Access Level:Open access
Keyword:Alzheimer, Lewy body disease, biomarker, diagnosis, mild cognitive impairment, a-synuclein
id ES_ee410f852136fa807ac9d13efb797ca9
oai_identifier_str oai:isabial.fundanetsuite.com:p3536
network_acronym_str ES
network_name_str España
repository_id_str
spelling Measurement of CSF a-synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer's disease.Garcia-Ayllon, Maria-SaludMonge-Argiles, Jose-AntonioMonge-Garcia, VictoriaNavarrete, FranciscoCortes-Gomez, Maria-AngelesSanchez-Paya, JoseManzanares, JorgeGasparini-Berenguer, RuthLeiva-Santana, CarlosSaez-Valero, JavierAlzheimer, Lewy body disease, biomarker, diagnosis, mild cognitive impairment, a-synucleinPrevious studies have indicated the potential of cerebrospinal fluid (CSF) a-synuclein (a-syn) to be an additional biomarker for improving differential diagnosis of Alzheimer's disease (AD). We evaluated a-syn diagnostic performance across a well-characterized patient cohort with long-term follow-up. For this purpose, CSF a-syn levels were determined in 25 subjects diagnosed with stable mild cognitive impairment (stable MCI; n = 25), 27 MCI cases due to AD (MCI-AD; n = 32), 24 MCI cases due to Lewy body disease (MCI-LBD; n = 24) and control subjects (Ctrl; n = 18). CSF a-syn levels discriminate between the four groups. There were higher a-syn levels in MCI-AD patients and lower levels in MCI-LBD patients. The combination of a-syn and P-tau resulted in a specificity of 99% and a sensitivity of 97% for MCI-AD. MCI-AD patients with early psychotic symptoms (n = 9) displayed a trend towards a decrease in P-tau and a-syn compared to the MCI-AD patients without psychotic symptoms (n = 23). We conclude that adding CSF a-syn to central core AD biomarkers improves an early differential diagnosis of MCI-AD from other forms of MCI. OPEN SCIENCE BADGES: This article has received a badge for *Open Materials* because it provided all relevant information to reproduce the study in the manuscript. The complete Open Science Disclosure form for this article can be found at the end of the article. More information about the Open Practices badges can be found at https://cos.io/our-services/open-science-badges/.Blackwell Publishing Inc.2019info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://isabial.portalinvestigacion.com/publicaciones3536JOURNAL OF NEUROCHEMISTRYISSN: 14714159ISSNe: 00223042reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicanteinstname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)Inglésinfo:eu-repo/semantics/openAccessoai:isabial.fundanetsuite.com:p35362026-06-12T10:20:37Z
dc.title.none.fl_str_mv Measurement of CSF a-synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer's disease.
title Measurement of CSF a-synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer's disease.
spellingShingle Measurement of CSF a-synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer's disease.
Garcia-Ayllon, Maria-Salud
Alzheimer, Lewy body disease, biomarker, diagnosis, mild cognitive impairment, a-synuclein
title_short Measurement of CSF a-synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer's disease.
title_full Measurement of CSF a-synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer's disease.
title_fullStr Measurement of CSF a-synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer's disease.
title_full_unstemmed Measurement of CSF a-synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer's disease.
title_sort Measurement of CSF a-synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer's disease.
dc.creator.none.fl_str_mv Garcia-Ayllon, Maria-Salud
Monge-Argiles, Jose-Antonio
Monge-Garcia, Victoria
Navarrete, Francisco
Cortes-Gomez, Maria-Angeles
Sanchez-Paya, Jose
Manzanares, Jorge
Gasparini-Berenguer, Ruth
Leiva-Santana, Carlos
Saez-Valero, Javier
author Garcia-Ayllon, Maria-Salud
author_facet Garcia-Ayllon, Maria-Salud
Monge-Argiles, Jose-Antonio
Monge-Garcia, Victoria
Navarrete, Francisco
Cortes-Gomez, Maria-Angeles
Sanchez-Paya, Jose
Manzanares, Jorge
Gasparini-Berenguer, Ruth
Leiva-Santana, Carlos
Saez-Valero, Javier
author_role author
author2 Monge-Argiles, Jose-Antonio
Monge-Garcia, Victoria
Navarrete, Francisco
Cortes-Gomez, Maria-Angeles
Sanchez-Paya, Jose
Manzanares, Jorge
Gasparini-Berenguer, Ruth
Leiva-Santana, Carlos
Saez-Valero, Javier
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Alzheimer, Lewy body disease, biomarker, diagnosis, mild cognitive impairment, a-synuclein
topic Alzheimer, Lewy body disease, biomarker, diagnosis, mild cognitive impairment, a-synuclein
description Previous studies have indicated the potential of cerebrospinal fluid (CSF) a-synuclein (a-syn) to be an additional biomarker for improving differential diagnosis of Alzheimer's disease (AD). We evaluated a-syn diagnostic performance across a well-characterized patient cohort with long-term follow-up. For this purpose, CSF a-syn levels were determined in 25 subjects diagnosed with stable mild cognitive impairment (stable MCI; n = 25), 27 MCI cases due to AD (MCI-AD; n = 32), 24 MCI cases due to Lewy body disease (MCI-LBD; n = 24) and control subjects (Ctrl; n = 18). CSF a-syn levels discriminate between the four groups. There were higher a-syn levels in MCI-AD patients and lower levels in MCI-LBD patients. The combination of a-syn and P-tau resulted in a specificity of 99% and a sensitivity of 97% for MCI-AD. MCI-AD patients with early psychotic symptoms (n = 9) displayed a trend towards a decrease in P-tau and a-syn compared to the MCI-AD patients without psychotic symptoms (n = 23). We conclude that adding CSF a-syn to central core AD biomarkers improves an early differential diagnosis of MCI-AD from other forms of MCI. OPEN SCIENCE BADGES: This article has received a badge for *Open Materials* because it provided all relevant information to reproduce the study in the manuscript. The complete Open Science Disclosure form for this article can be found at the end of the article. More information about the Open Practices badges can be found at https://cos.io/our-services/open-science-badges/.
publishDate 2019
dc.date.none.fl_str_mv 2019
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://isabial.portalinvestigacion.com/publicaciones3536
url https://isabial.portalinvestigacion.com/publicaciones3536
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Blackwell Publishing Inc.
publisher.none.fl_str_mv Blackwell Publishing Inc.
dc.source.none.fl_str_mv JOURNAL OF NEUROCHEMISTRY
ISSN: 14714159
ISSNe: 00223042
reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
instname_str Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
reponame_str r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
collection r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423628753305600
score 15,198674

Similar Items